Department of Psychiatry, S.M.S. Medical College, Jaipur, India.
Indian J Psychiatry. 2011 Apr;53(2):128-33. doi: 10.4103/0019-5545.82537.
Persons with schizophrenia are reported to be more likely to die from cardiovascular illness than those in the general population, and are at a greater risk of developing obesity, diabetes type 2, hypertension and dyslipidemias. Antipsychotic drugs used in the treatment of schizophrenia and other psychotic illnesses can induce weight gain, with some agents having a greater propensity to do so than others. These adverse effects associated with second-generation antipsychotics are also part of the metabolic syndrome.
The aim of this study was to evaluate the emergence of metabolic syndrome due to second-generation antipsychotics as compared with conventional (typical) antipsychotics.
A prospective interventional study was conducted at the Psychiatric Centre, Jaipur. The study included 120 patients, both indoor and outdoor, suffering from schizophrenia diagnosed using the ICD-10 criteria. The patients were grouped into four categories, i.e. control group and three study groups, each group having 30 patients.
Thirty patients were given conventional antipsychotics and 90 were given second-generation antipsychotics, including risperidone, olanzapine and clozapine. Metabolic parameters were taken before onset of drug treatment therapy and after 4 months. The changes in metabolic parameters were compared using appropriate statistical tools.
Chi square chart and Unpaired t-test were used for statistical analysis using a computer.
11.66% of the patients developed metabolic syndrome after 4 months of antipsychotic medication.
Second-generation antipsychotics cause significantly more changes in the metabolic parameters, increasing the chances of developing metabolic syndrome and associated disorders like diabetes mellitus type-II and cerebrovascular accidents. Olanzapine is the antipsychotic drug that has the maximum potential to cause metabolic syndrome.
据报道，精神分裂症患者死于心血管疾病的风险高于普通人群，并且更容易患肥胖症、2 型糖尿病、高血压和血脂异常。用于治疗精神分裂症和其他精神病的抗精神病药物会导致体重增加，一些药物比其他药物更有这种倾向。这些与第二代抗精神病药物相关的不良反应也是代谢综合征的一部分。
本研究旨在评估第二代抗精神病药物与传统（典型）抗精神病药物相比引起代谢综合征的情况。
这是一项在斋浦尔精神中心进行的前瞻性干预研究。该研究纳入了 120 名符合 ICD-10 标准诊断的精神分裂症住院和门诊患者。将患者分为四组，即对照组和三组研究组，每组 30 名患者。
30 名患者给予传统抗精神病药物，90 名患者给予第二代抗精神病药物，包括利培酮、奥氮平和氯氮平。在开始药物治疗前和 4 个月后测量代谢参数。使用适当的统计工具比较代谢参数的变化。
使用计算机进行统计分析时，采用卡方检验和独立样本 t 检验。
在接受抗精神病药物治疗 4 个月后，有 11.66%的患者出现代谢综合征。
第二代抗精神病药物会导致代谢参数发生显著变化，增加发生代谢综合征和相关疾病（如 2 型糖尿病和脑血管意外）的几率。奥氮平是最有可能引起代谢综合征的抗精神病药物。
